Influenza Virus-Like Particles Presenting both <i>Toxoplasma gondii</i> ROP4 and ROP13 Enhance Protection against <i>T. gondii</i> Infection

• Main Authors: Hae-Ji Kang (Author), Su-Hwa Lee (Author), Min-Ju Kim (Author), Ki-Back Chu (Author), Dong-Hun Lee (Author), Manika Chopra (Author), Hyo-Jick Choi (Author), Hyunwoo Park (Author), Hui Jin (Author), Fu-Shi Quan (Author)
• Format: Book
• Published: MDPI AG, 2019-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 1999-4923; 10.3390/pharmaceutics11070342
• Keywords: <i>Toxoplasma gondii</i>; virus-like particle; vaccine; protection; ROP4; ROP13; Pharmacy and materia medica; RS1-441
• Source: Pharmaceutics, Vol 11, Iss 7, p 342 (2019)

Rhoptry organelle proteins (ROPs) secreted by <i>Toxoplasma gondii</i> (<i>T. gondii</i>) play a critical role during parasite invasion into host cells. In this study, virus-like particles (VLPs) vaccines containing ROP4 and/or ROP13 together with influenza M1 were generated. ROP4+ROP13 VLPs were produced by combining ROP4 VLPs with ROP13 VLPs, and ROP(4 + 13) VLPs by co-infecting insect cells with recombinant baculovirus expressing ROP4 or ROP13. Mice intranasally immunized with ROP(4 + 13) VLPs showed significantly higher levels of IgG, IgG1, IgG2a and IgA antibody responses in sera compared to ROP4+ROP13VLPs. Upon challenge infection by oral route, mice immunized with ROP(4 + 13) VLPs elicited higher levels of IgG and IgA antibody responses in fecal, urine, intestine and vaginal samples as well as CD4⁺ T, CD8⁺ T cells, and germinal center B cell responses compared to other type of vaccines, ROP4 VLPs, ROP13 VLPs, and ROP4+ROP13 VLPs. ROP(4 + 13) VLPs vaccination showed a significant decrease in the size and number of cyst in the brain and less body weight loss compared to combination ROP4+ROP13 VLPs upon challenge infection with <i>T. gondii</i> ME49. These results indicated that the ROP(4 + 13) VLPs vaccination provided enhanced protection against <i>T. gondii</i> infection compared to ROP4+ROP13 VLPs, providing an important insight into vaccine design strategy for <i>T. gondii</i> VLPs vaccines.